Dercum’s Disease Market Research Report Information by Treatment (Surgery, Medication {Diuretics, Non-Steroidal Anti-Inflammatory Drug, Corticosteroids, and Others}, Liposuction, Electrotherapy, Acupuncture, and Others) by End user (Hospital & Clinics, Ambulatory Surgical Centers, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2034

Dercum’s Disease Market Overview

As per MRFR analysis, the Dercum’s Disease Market Size was estimated at 13.31 (USD Billion) in 2024. The Dercum’s Disease Market Industry is expected to grow from 14.21 (USD Billion) in 2025 to 25.61 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.76% during the forecast period (2025 - 2034). The rising prevalence of rare diseases and increasing research and development activities are driving market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In May 2023, the Phase IIa trial for adiposis dolorosa observed an increase in PTSR (Post-Treatment Symptom Relief) with the administration of CBL-514, a drug developed by Caliway Biopharmaceuticals. The administration of the medicine led to a 10% rise in post-traumatic stress response (PTSR), bringing it to a level of 19%, in patients diagnosed with adiposis dolorosa (also referred to as Dercum's disease or Anders disease). A randomized, open-label research was conducted to investigate the efficacy of CBL-514 injections in treating lipomas associated with Dercum's disease. Researchers are currently investigating the use of a chemical named CBL-514 to address conditions such as cellulite, Dercum's disease, oedematous fibrosclerotic panniculopathy, and benign tumors like lipomas. The medicine candidate is administered through either subcutaneous or intravenous injections.

Dercum’s Disease Market Trends

• The rising prevalence of rare diseases to boost the market growth

Rare diseases such as adiposis dolorosa, and lipomas along with the ongoing COVID-19 pandemic, account for a substantial burden globally. According to the NCBI survey, held in February 2021, approximately 2500 people per year with loose connective (adipose) tissue disease were seen, most patients with lipedema, six patients with FML-Type DD, and 10 patients with angiolipoma-type Dercum’s disease. Additionally, the same survey suggested that the prevalence of Dercum’s disease is 0.64% in the population, and the prevalence of lipedema in the USA is thought to be 11% in women though the range is 5 to 39%. A majority of people with dercum’s disease are women.

Furthermore, dercum's disease is characterized by multiple, painful growths of fatty tissue (lipomas). So, the number of patients suffering from rare diseases is increasing globally. Moreover, the increasing cases of COVID-19 also have a significant impact on the market growth of the dercum’s disease. Such a rise in the number of diseases cases is anticipated to augment the demand for dercum’s disease globally.

Dercum’s Disease Market Segment Insights

Dercum’s Disease Treatment Insights

The Market segments of Dercum’s Disease, based on treatment, includes surgery, medication, liposuction, electrotherapy, acupuncture, and others. The surgery segment held the majority share in 2022 in the Dercum’s Disease Market revenue. This is due to the rising number of cases of decrum's disease surgeries. Moreover, the surgical option involves the surgical removal of the fatty tumors in the body. However, during this surgery, multiple scars are created. This surgical intervention may help patients reduce pain.

Figure 2: DERCUM’S DISEASE MARKET, BY TREATMENT, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Dercum’s Disease End User Insights

The Dercum’s Disease Market segmentation is based on end user that includes hospital & clinics ambulatory surgical centers others. The hospital & clinics segment has dominated the market in 2022 and ambulatory surgical centers are projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to the increasing healthcare expenditure and increasing number of multispecialty & community hospitals across the globe.

Dercum’s Disease Distribution Channel Insights

The Market segmentation of Dercum’s Disease, based on distribution channel, includes hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the majority share in 2022 in the Market revenue of Dercum’s Disease. This is due to the increased hospital admissions for the treatment of dercum’s disease. In addition, hospital pharmacies are those in hospitals that provide all the medications used in the facility. Hospitalization is necessary for treatments like operations for patients with dercum's disease.

Dercum’s Disease Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America dercum’s disease market accounted for the largest market share in 2022. This is due to the favorable government act towards for the development of rare disease drug & devices as well as approval of drug in the region. For instance, In the US and Canada, the Orphan Drug Act (ODA) provides incentives to drug and device manufacturers to encourage them to develop drugs and devices for rare diseases. Furthermore, regulatory changes and scientific advancements in the North American region have dramatically increased the number of orphan drugs market.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.

Figure 3: DERCUM’S DISEASE MARKET SHARE BY REGION 2022 & 2032

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe dercum’s disease market accounts for the second-largest market share due to the research studies through healthcare regulatory bodies for the treatment of dercum’s disease and favorable policy and public affairs strategies. further, the Germany market of dercum’s disease was attributed to hold the largest market share, and the France market of dercum’s disease is expected to fastest-growing market in the European region.

The Asia-Pacific dercum’s disease market is expected to grow at a significant share from 2023 to 2032. This is due to the increasing investment, clinical trial studies, and companies' R&D for drugs to treat adipose dolorosa in the Asia-Pacific region. Moreover, China market of dercum’s disease is expected to hold the largest market share, and India market of dercum’s disease is expected fastest-growing market in the Asia-Pacific region.

Moreover, in August 2022, as per ClinicalTrials.gov, Raziel Therapeutics Ltd. sponsored the safety and efficacy of RZL-012 injection clinical trials in Chinese patients and found to be safe and well tolerated in Chinese population. Furthermore, increasing investment, clinical trial studies, and companies' R&D for drugs to treat adipose dolorosa, these factors are likely to have considerable market growth for the dercum’s disease.

The Rest of the World is segmented into the Middle East, Africa, and Latin America. The market of dercum’s disease in the above-mentioned regions is likely to witness growth due to raising of funds and investments in the region through companies. Moreover, there is a lack of awareness among women about how to manage their health during puberty, pregnancy, and menopause, which is another factor giving rise to the adipose dolorosa in women. Hence, lack of awareness about the disease and its management, raising funds, and expansion of companies in other regions fuel the region's growth.

Dercum’s Disease Key Market Players & Competitive Insights

The Dercum’s Disease Market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reached across the globe with diverse product portfolios. Companies such as Johnson & Johnson Services, Inc (US), Pfizer Inc (US), Abbvie, Inc (US), and Novartis International AG (Switzerland) dominate the Dercum’s Disease Market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the global dercum’s disease industry to benefit clients and expand the dercum’s disease market sector is to manufacture locally to reduce operating costs.

Johnson & Johnson Services, Inc. (J&J Services) manufactures medical devices for various specialties such as orthopedics, cardiovascular diseases, and many others. J&J Services has acquired and merged with various other companies to expand its portfolio of endoscopic devices, pharmaceutical, and consumer health products. The company operates through its various subsidiary Janssen Pharmaceutica, Neutrogena, DePuy Synthes Companies, Ethicon Inc., Janssen-Cilag, Actelion, LifeScan, Inc., Johnson & Johnson Vision Care, Inc., and others. Under its Johnson & Johnson Surgical Vision business, the company offers different eye care products which include contact and intraocular lenses, under the ACUVUE brand.

Also, Pfizer Inc. (Pfizer) is a leading research-based biopharmaceutical company that applies science and resources to provide innovative treatments that extend and significantly improve lives. Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs), and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. Furthermore, the company supplies its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East.

Key Companies in the market of dercum’s disease include

• Pfizer Inc (US)






• Abbvie, Inc (US)






• Johnson & Johnson Services, Inc (US)






• GlaxoSmithKline plc (UK)






• Bausch & Lomb Incorporated (Canada)






• Caliway (Taiwan)






• Raziel Therapeutics Ltd (Israel)






• Nivarta, Inc (US)






• BHR Pharmaceuticals Ltd (UK)






• Novartis International AG (Switzerland)

Dercum’s Disease Industry Developments

September 2020: Raziel Therapeutics Ltd (Israel) entered into an agreement with Fosun Pharma (China) for RZL 012. In accordance with the contract, Raziel Therapeutics is eligible to receive tiered royalty payments on future net sales, additional potential sales milestone payments of up to USD 47 million, and potential payments of USD 27 million between now and the Territory's marketing approval of RZL 012.

Dercum’s Disease Market Segmentation

Dercum’s Disease Treatment Outlook

• Surgery






• Medication
  
  
  
  • Diuretics
  
  
  
  
  
  
  • Non-Steroidal Anti-Inflammatory Drug
  
  
  
  
  
  
  • Corticosteroids
  
  
  
  
  
  
  • Others
  
  
  
  






• Liposuction






• Electrotherapy






• Acupuncture






• Others

Dercum’s Disease End user Outlook

• Hospital & Clinics






• Ambulatory Surgical Centers






• Others

Dercum’s Disease Distribution Channel Outlook

• Hospital Pharmacies






• Retail Pharmacies






• Others

Dercum’s Disease Regional Outlook

• North America
  
  
  
  • US
  
  
  
  
  
  
  • Canada
  
  
  
  






• Europe
  
  
  
  • Germany
  
  
  
  
  
  
  • France
  
  
  
  
  
  
  • UK
  
  
  
  
  
  
  • Italy
  
  
  
  
  
  
  • Spain
  
  
  
  
  
  
  • Rest of Europe
  
  
  
  






• Asia-Pacific
  
  
  
  • China
  
  
  
  
  
  
  • Japan
  
  
  
  
  
  
  • India
  
  
  
  
  
  
  • Australia
  
  
  
  
  
  
  • South Korea
  
  
  
  
  
  
  • Rest of Asia-Pacific
  
  
  
  






• Rest of the World
  
  
  
  • Middle East
  
  
  
  
  
  
  • Africa
  
  
  
  
  
  
  • Latin America
  
  
  
  

Report Attribute/Metric	Details
Market Size 2024	13.31 (USD Billion)
Market Size 2025	14.21 (USD Billion)
Market Size 2034	25.61 (USD Billion)
Compound Annual Growth Rate (CAGR)	6.76 % (2025 - 2034)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2034
Historical Data	2020 - 2024
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Treatment, End user, and Distribution Channel, and Region
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Key Companies Profiled	Pfizer Inc (US), Abbvie, Inc (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc (UK), Bausch & Lomb Incorporated (Canada), Caliway (Taiwan), Raziel Therapeutics Ltd (Israel), Nivarta, Inc (US), BHR Pharmaceuticals Ltd (UK), and Novartis International AG (Switzerland)
Key Market Opportunities	·       Rising number of strategic initiatives
Key Market Dynamics	·       Rising prevalence of rare diseases ·       increasing research and development activities